Psyllium (Plantago ovata)

Table of Contents

1. What Psyllium Is
2. The Gel: How It Works
3. Cholesterol and the Heart
4. Blood Sugar and Diabetes
5. Constipation
6. IBS, Loose Stools and Haemorrhoids
7. Weight, Appetite and Blood Pressure
8. Forms and Doses Used in Studies
9. Safety: Choking, Allergy and Medicines
10. Where the Evidence Stands
11. Key Research Papers
12. Connections
13. Featured Videos

What Psyllium Is

Plantago ovata belongs to the same genus as the broadleaf and ribwort plantains that grow in lawns across the world — this site's Plantain page covers those leafy relatives, and its Psyllium Relatives article explains why the leaf does not borrow the husk's evidence. Psyllium is a different species and, more importantly, a different plant part.

• The part used. The European Medicines Agency defines ispaghula husk as “the episperm and collapsed adjacent layers removed from the seeds” of Plantago ovata — in plain words, the seed coat, separated from the seed by milling. The whole seed is a separate product with its own monograph.
• The names. US food regulations list the husk of P. ovata as “blond psyllium or Indian psyllium”, alongside P. indica and P. psyllium (21 CFR 101.81). Ispaghula, isabgol and psyllium husk all refer to the same material.
• Where it comes from. India is the largest producer and exporter of psyllium husk, and most of the crop is grown and processed in the state of Gujarat (Vikaspedia, Government of India).
• What it is made of. According to the EMA monograph, the husk is about 85% water-soluble fibre and can absorb up to 40 times its own weight in water. That swelling is the whole story: psyllium has no single “active compound” in the way a medicinal herb usually does. Its effects are physical.

Because the active principle is a physical property rather than a chemical one, psyllium is studied less like a herb and more like a food ingredient or an over-the-counter laxative. That is one reason it has accumulated so many controlled trials.

The Gel: How It Works

Stirred into water, psyllium husk forms a thick, slippery gel. A 2017 review of fibre physics by McRorie and McKeown explains how that one property produces effects in two different parts of the gut.

In the small intestine: viscosity

The review describes clinically meaningful cholesterol lowering and improved blood-sugar control as “highly correlated with the viscosity of soluble fibers”. High-viscosity, gel-forming fibres — beta-glucan from oats and barley, psyllium, and raw guar gum — showed these effects, whereas non-viscous soluble fibres such as inulin and wheat dextrin, and insoluble fibres such as wheat bran, did not. A gel slows the mixing and absorption of food in the small intestine; that is the proposed reason psyllium blunts the rise in blood sugar after a meal and, by trapping bile acids, pulls cholesterol out of circulation to replace them.

In the large intestine: a gel that holds its water

The same review lists only two ways a fibre produces a laxative effect: coarse insoluble particles (such as wheat bran) that irritate the gut lining, and the high water-holding capacity of a gel-forming fibre like psyllium that “resists dehydration”. Both depend on the fibre surviving to the stool largely intact. The EMA monograph describes the husk as partly fermentable (in laboratory tests, 72% remained unfermented) and lists a laxative effect within 12 to 24 hours of a single dose, sometimes reaching its maximum after 2 to 3 days.

Because the gel holds water, it can soften hard stool and also firm up loose stool — which is why the same supplement appears in research on both constipation and diarrhoea.

Effects on gut bacteria

Psyllium is not mainly a “prebiotic”, but it does change the gut environment. In two small placebo-controlled trials (8 healthy volunteers and 16 people with constipation), 7 days of psyllium increased stool water and shifted the stool bacteria, with larger changes in the constipated group, including increases in butyrate-producing genera that correlated with stool water.

Cholesterol and the Heart

This is psyllium's best-quantified effect.

• 28 randomised trials, 1,924 people. A 2018 meta-analysis found that a median dose of about 10.2 g of psyllium a day lowered LDL cholesterol by 0.33 mmol/L (roughly 13 mg/dL), non-HDL cholesterol by 0.39 mmol/L and apolipoprotein B by 0.05 g/L. The authors graded the LDL result as moderate-quality evidence, downgraded for inconsistency between trials.
• 29 trials, 2,769 people. A 2024 meta-analysis of Plantago consumption reported reductions of 0.28 mmol/L in total cholesterol and 0.35 mmol/L in LDL, with no substantial change in HDL or triglycerides. The authors estimated this would correspond to a 7% lower risk of cardiovascular events — an estimate, not a measured outcome.
• An umbrella review. A 2021 review of systematic reviews graded foods high in soluble fibre — naming oats, barley and psyllium — as causing at least moderate (0.20–0.40 mmol/L) LDL reductions, with high certainty.
• A sense of scale. An older meta-analysis of 67 trials (1999) found oat, psyllium and pectin fibre lowered cholesterol by similar amounts per gram, and judged the effect small within practical intakes.

Regulators have acted on this evidence. The US FDA authorises a health claim that soluble fibre from psyllium husk, as part of a diet low in saturated fat and cholesterol, may reduce the risk of heart disease; the regulation names 7 g or more of soluble fibre from psyllium husk per day as the qualifying intake, and at least 1.7 g per serving of a labelled food (21 CFR 101.81). The EMA lists use “as an adjuvant to diet in hypercholesterolemia”, reports an LDL reduction of approximately 7% in mild to moderate hypercholesterolaemia, and notes that studies of cardiovascular events and total mortality are not available (EMA).

Full details, including the trials of psyllium added to statins, are in Psyllium: Cholesterol and Heart Health.

Blood Sugar and Diabetes

• 19 trials, 962 adults (2024). Compared with placebo, psyllium significantly lowered fasting blood sugar (weighted mean difference −6.89), HbA1c (−0.75) and HOMA-IR, a measure of insulin resistance (−1.17); fasting insulin did not change significantly. The HbA1c effect was not significant at doses below 10 g a day.
• People with diabetes (2020). A meta-analysis of 8 trials (395 participants) reported reductions in fasting blood sugar, HbA1c, LDL and triglycerides, but no significant change in weight or body mass index — and very high heterogeneity between studies (I² of 97–99%), which means the trials disagreed a great deal about the size of the effect.
• Compared with other fibres (2023). A network meta-analysis of 46 trials in type 2 diabetes ranked galactomannans (such as guar and fenugreek gum) highest for HbA1c and fasting glucose; psyllium and beta-glucans ranked highest for fasting insulin and insulin resistance. Most comparisons had low or moderate certainty.

The EMA monograph states that people with diabetes take ispaghula husk under medical supervision because their diabetes medicines may need adjusting. More in Psyllium: Blood Sugar and Diabetes.

Constipation

Psyllium's oldest and most common use is as a bulk-forming laxative, and here the evidence is solid but less dramatic than marketing suggests.

• 16 trials, 1,251 adults (2022). Across all fibres, 66% of people responded to fibre and 41% to control. Psyllium and pectin were the fibres with significant effects; benefits on stool frequency appeared with doses above 10 g a day and treatment for at least 4 weeks. Flatulence was more common with fibre.
• Over-the-counter laxatives compared (2021). A systematic review of 41 trials graded the evidence as good (grade A) for polyethylene glycol and senna, and moderate (grade B) for psyllium, magnesium salts, other stimulant laxatives and several fruits. No serious adverse events were reported.
• Against a stool softener (1998). In 170 people with chronic constipation, psyllium (5.1 g twice daily) increased stool water and stool output more than docusate sodium. This trial was run by a psyllium-product manufacturer.
• Against fruit. In head-to-head trials, prunes (100 g a day) improved stool frequency more than psyllium in one trial, and a 2024 meta-analysis found fruits — kiwifruit in particular — produced slightly more bowel movements per week than psyllium. In a US trial of kiwifruit, prunes or psyllium, all three improved complete bowel movements, but side effects were most common with psyllium.

The EMA lists ispaghula husk for “habitual constipation” and notes that the effect begins 12–24 hours after a dose. See Psyllium: IBS, Constipation and Diarrhoea.

IBS, Loose Stools and Haemorrhoids

A 2017 review of diet in irritable bowel syndrome (IBS) concluded that there is insufficient evidence for fibres other than psyllium in IBS — making psyllium the one fibre with reasonable support in that condition. A separate review of people for whom a low-FODMAP diet does not work describes psyllium's “exceptional water-holding capacity” as the reason it is used to produce more formed stools in people with fast gut transit.

The EMA monograph lists ispaghula husk as an adjuvant in constipation-predominant IBS, and for conditions in which easy passage of soft stool is wanted — anal fissures, haemorrhoids and recovery after anal or rectal surgery.

This is also a place where fibre is not interchangeable. The physics review cited above notes that fermentable soluble fibres such as inulin and fructo-oligosaccharides do not provide a laxative effect, and that fine wheat bran can even be constipating.

Weight, Appetite and Blood Pressure

• Weight. A 2023 meta-analysis of 6 trials (354 overweight or obese adults) reported that psyllium taken just before meals (average 10.8 g a day for 4.8 months) lowered body weight by 2.1 kg, BMI by 0.8 and waist circumference by 2.2 cm. Its authors were employees of a psyllium-product manufacturer. An independent 2023 network meta-analysis of 111 trials of 18 supplements gave psyllium a weight difference of 3.7 kg with moderate certainty, and described the effects of the supplements in general as small.
• Appetite. Two short crossover trials found that 6.8 g of psyllium before meals reduced hunger and desire to eat between meals compared with placebo.
• Blood pressure. A 2020 meta-analysis of 11 trials (592 participants) found a 2.04 mmHg reduction in systolic blood pressure, larger in people who started with higher blood pressure.

The weight-loss figures are modest, and the people in these trials were usually also following a diet. The 2020 meta-analysis in people with diabetes, above, found no significant weight change.

Forms and Doses Used in Studies

Psyllium is sold as husk flakes, fine powder, capsules and wafers, and it is added to some breakfast cereals and baked goods. The amounts below are what trials and regulators describe; they are reported here as information, not as a dosing guide.

• EMA monograph (constipation and stool softening): 7–11 g a day for adolescents and adults, in one to three doses; 3–8 g a day for children aged 6–12. The monograph does not recommend use under 6 years of age.
• EMA monograph (fibre supplementation, IBS, cholesterol): 7–20 g a day for adolescents and adults, in one to three doses.
• Liquid: the EMA gives “30 ml of water per 1 g of herbal substance” as an example of a sufficient amount, describes taking it during the day and not immediately before bed, and spacing it at least half an hour to an hour from other medicines.
• Cholesterol trials: a median of about 10.2 g a day in the largest meta-analysis; the FDA claim is built on 7 g of soluble fibre from psyllium husk a day.
• Constipation trials: benefits were clearest above 10 g a day for at least 4 weeks.

The full monograph is available from the European Medicines Agency (PDF).

Safety: Choking, Allergy and Medicines

Psyllium is not absorbed into the bloodstream, and the main safety issues follow from what it is: a powder that swells, and a plant protein that can sensitise.

Choking and blockage

US regulations state that “esophageal obstruction and asphyxiation have been associated with the ingestion” of water-soluble gums and hydrophilic mucilloids, including psyllium, and that these are significant risks when products are taken without adequate fluid or by people with oesophageal narrowing or difficulty swallowing. Over-the-counter products in dry form must carry a “Choking” warning, and granular psyllium laxatives are not generally recognised as safe and effective without an approved application (21 CFR 201.319). A 1995 review of “pharmacobezoars” — masses formed from medicines inside the gut — lists psyllium preparations among the causes, usually in people with slow gut movement, dehydration, or narrowed anatomy.

Allergy

Case reports describe serious allergic reactions. Two nurses who had developed nasal and eye symptoms while handling psyllium went on to have anaphylactic reactions when they later swallowed it. A Spanish case series describes occupational asthma in a young man working in psyllium manufacture. The EMA monograph states that ispaghula “contains potent allergens”, that sensitisation through inhaled powder occurs in people with continued occupational contact such as healthcare workers and caregivers, and that it is more frequent in people with a tendency to allergies.

Medicines

The EMA monograph lists delayed absorption of minerals, vitamin B12, cardiac glycosides, coumarin anticoagulants, carbamazepine and lithium when taken at the same time, notes that thyroid hormone doses may need adjusting, and that diabetes treatment may need adjusting. Details for all three topics are in Psyllium: Allergy, Choking and Drug Timing.

Everyday side effects, pregnancy and breastfeeding

Flatulence and bloating are the common complaints in trials. The EMA notes limited data in pregnancy (fewer than 300 pregnancy outcomes) and that use “may be considered” in pregnancy and breastfeeding when dietary change has not worked. The US National Library of Medicine's LactMed database states that psyllium is not absorbed, cannot enter breast milk, and is acceptable during breastfeeding.

Where the Evidence Stands

• Strongest: LDL cholesterol (two large meta-analyses, moderate-quality evidence, regulator-recognised) and chronic constipation (meta-analysis of 16 trials; grade B in an independent review).
• Supported but variable: fasting blood sugar and HbA1c, with high heterogeneity between trials; IBS, where psyllium is the fibre with the most support.
• Modest: body weight (about 2–4 kg in meta-analyses, partly industry-authored) and systolic blood pressure (about 2 mmHg).
• Missing: trials measuring heart attacks, strokes or deaths. The cholesterol benefit is measured in blood tests; its effect on events is inferred.
• Real hazards: blockage when taken with too little liquid or by people with swallowing problems; allergy, especially after occupational inhalation; and interference with the timing of other oral medicines.

Several of the most-cited psyllium papers were written or funded by companies that sell psyllium products or psyllium-enriched foods; this is noted next to each such paper on the sub-pages. Independent meta-analyses reach broadly similar conclusions on cholesterol and constipation. Decisions about supplements, especially alongside prescription medicines, belong with a clinician.

Key Research Papers

1. Jovanovski E, Yashpal S, Komishon A, et al. Effect of psyllium (Plantago ovata) fiber on LDL cholesterol and alternative lipid targets, non-HDL cholesterol and apolipoprotein B: a systematic review and meta-analysis of randomized controlled trials. The American journal of clinical nutrition. 2018;108(5):922-932. — 28 trials; median 10.2 g/day lowered LDL, non-HDL cholesterol and apoB. PubMed PMID: 30239559
2. Zhu R, Lei Y, Wang S, et al. Plantago consumption significantly reduces total cholesterol and low-density lipoprotein cholesterol in adults: A systematic review and meta-analysis. Nutrition research (New York, N.Y.). 2024;126:123-137. — 29 trials; total and LDL cholesterol fell, HDL and triglycerides did not change. PubMed PMID: 38688104
3. Schoeneck M, Iggman D. The effects of foods on LDL cholesterol levels: A systematic review of the accumulated evidence from systematic reviews and meta-analyses of randomized controlled trials. Nutrition, metabolism, and cardiovascular diseases : NMCD. 2021;31(5):1325-1338. — umbrella review grading soluble-fibre foods including psyllium as high-certainty LDL reducers. PubMed PMID: 33762150
4. Brown L, Rosner B, Willett WW, et al. Cholesterol-lowering effects of dietary fiber: a meta-analysis. The American journal of clinical nutrition. 1999;69(1):30-42. — 67 trials; oat, psyllium and pectin fibre lowered cholesterol by similar, small amounts per gram. PubMed PMID: 9925120
5. Gholami Z, Clark CCT, Paknahad Z. The effect of psyllium on fasting blood sugar, HbA1c, HOMA IR, and insulin control: a GRADE-assessed systematic review and meta-analysis of randomized controlled trials. BMC endocrine disorders. 2024;24(1):82. — 19 trials; fasting glucose, HbA1c and HOMA-IR fell, insulin did not. PubMed PMID: 38844885
6. Xiao Z, Chen H, Zhang Y, et al. The effect of psyllium consumption on weight, body mass index, lipid profile, and glucose metabolism in diabetic patients: A systematic review and dose-response meta-analysis of randomized controlled trials. Phytotherapy research : PTR. 2020;34(6):1237-1247. — 8 trials in people with diabetes; glucose and lipids improved, weight did not; very high heterogeneity. PubMed PMID: 31919936
7. McRorie JW Jr, McKeown NM. Understanding the Physics of Functional Fibers in the Gastrointestinal Tract: An Evidence-Based Approach to Resolving Enduring Misconceptions about Insoluble and Soluble Fiber. Journal of the Academy of Nutrition and Dietetics. 2017;117(2):251-264. — why viscosity and water-holding explain which fibres work. PubMed PMID: 27863994
8. van der Schoot A, Drysdale C, Whelan K, et al. The Effect of Fiber Supplementation on Chronic Constipation in Adults: An Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials. The American journal of clinical nutrition. 2022;116(4):953-969. — 16 trials; psyllium among the fibres that improved constipation, best above 10 g/day. PubMed PMID: 35816465
9. Rao SSC, Brenner DM. Efficacy and Safety of Over-the-Counter Therapies for Chronic Constipation: An Updated Systematic Review. The American journal of gastroenterology. 2021;116(6):1156-1181. — grade B evidence for psyllium among over-the-counter constipation treatments. PubMed PMID: 33767108
10. McRorie JW, Daggy BP, Morel JG, et al. Psyllium is superior to docusate sodium for treatment of chronic constipation. Alimentary pharmacology & therapeutics. 1998;12(5):491-7. — psyllium softened stools more than docusate; manufacturer-run trial. PubMed PMID: 9663731
11. Jalanka J, Major G, Murray K, et al. The Effect of Psyllium Husk on Intestinal Microbiota in Constipated Patients and Healthy Controls. International journal of molecular sciences. 2019;20(2). — psyllium increased stool water and shifted stool bacteria, most in constipated patients. PubMed PMID: 30669509
12. Dimidi E, Rossi M, Whelan K. Irritable bowel syndrome and diet: where are we in 2018? Current opinion in clinical nutrition and metabolic care. 2017;20(6):456-463. — insufficient evidence for fibres other than psyllium in IBS. PubMed PMID: 28872467
13. Gibb RD, Sloan KJ, McRorie JW Jr. Psyllium is a natural nonfermented gel-forming fiber that is effective for weight loss: A comprehensive review and meta-analysis. Journal of the American Association of Nurse Practitioners. 2023;35(8):468-476. — 6 trials; 2.1 kg weight difference; authors employed by a psyllium-product manufacturer. PubMed PMID: 37163454
14. Clark CCT, Salek M, Aghabagheri E, et al. The effect of psyllium supplementation on blood pressure: a systematic review and meta-analysis of randomized controlled trials. The Korean journal of internal medicine. 2020;35(6):1385-1399. — 11 trials; systolic blood pressure 2.04 mmHg lower. PubMed PMID: 32066221
15. Sussman GL, Dorian W. Psyllium anaphylaxis. Allergy proceedings : the official journal of regional and state allergy societies. 1990;11(5):241-2. — two nurses sensitised at work who developed anaphylaxis after swallowing psyllium. PubMed PMID: 2258044
16. Stack PE, Thomas E. Pharmacobezoar: an evolving new entity. Digestive diseases (Basel, Switzerland). 1995;13(6):356-64. — review listing psyllium preparations among medicines that can form gut masses. PubMed PMID: 8590522
17. Psyllium. Drugs and Lactation Database (LactMed®). Bethesda (MD): National Institute of Child Health and Human Development; 2006–. — not absorbed; considered acceptable during breastfeeding. PubMed PMID: 30000405

PubMed Topic Searches

1. Psyllium and LDL cholesterol
2. Psyllium and glycaemic control
3. Psyllium and constipation trials
4. Psyllium allergy and occupational asthma

Back to Table of Contents

Connections

• Digestive and Gut Herbs — the category this herb belongs to
• Psyllium: Benefits Deep Dive — the evidence hub and four detailed articles
• Cholesterol and Heart Health — the LDL meta-analyses and the FDA claim
• Blood Sugar and Diabetes — HbA1c, fasting glucose and insulin resistance
• IBS, Constipation and Diarrhoea — a bulk laxative that works both ways
• Allergy, Choking and Drug Timing — the real hazards
• Plantain: Its Psyllium Relatives — why the lawn plantain does not share psyllium's evidence
• Dietary Fiber — the wider family of fibres
• Constipation — causes and treatments
• Irritable Bowel Syndrome — the condition, its subtypes and treatments
• Cholesterol Management — where diet fits beside medicines
• Type 2 Diabetes — the condition the glucose trials studied
• Oats: Beta-Glucan and Cholesterol — the other fibre with an FDA heart claim
• Senna — a stimulant laxative, a different mechanism
• Prunes: Digestion and Constipation — compared with psyllium head to head
• Anaphylaxis — the severe allergic reaction reported with psyllium

Back to Table of Contents

Featured Videos